Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease

Patent metadata

Field	Value
Publication number	US-11007228-B2
Application number	US-201716075517-A
Country	US
Kind code	B2
Filing date	Feb 3, 2017
Priority date	Feb 5, 2016
Publication date	May 18, 2021
Grant date	May 18, 2021

Abstract

The present invention relates to a pharmaceutical composition containing stem cells in which vascular endothelial growth factor (VEGF) is overexpressed as an effective ingredient for preventing or treating neurodegenerative diseases. The stem cells in which VEGF is overexpressed according to the present invention effectively act against the neurodegenerative disease-induced VEGF reduction of neural stem cells in the SVC to inhibit the abnormal migration of neural stem cells, suppress inflammatory responses, and restrain the accumulation of cholesterol and spingolipids in the cerebral cortex, thus restoring the behavior exercise capacity of animal models, whereby the pharmaceutical composition can be used as an effective therapeutic agent for neurodegenerative diseases.

First claim

What is claimed is:

1. A method for treating a neurodegenerative disease in a subject in need thereof, the method comprising administering an effective amount of a composition comprising stem cells overexpressing vascular endothelial growth factor (VEGF) as an active ingredient to a subventricular zone (SVZ) of the subject, wherein the neurodegenerative disease is selected from the group consisting of Niemann-Pick disease, Gaucher disease, Fabry disease, Tay-Sachs disease, and Sandhoff disease.

2. The method of claim 1 , wherein the stem cells are at least any one selected from the group consisting of adult stem cells, embryonic stem cells, mesenchymal stem cells, tumor stem cells, and induced pluripotent stem cells.

3. The method of claim 2 , wherein the adult stem cells are neural stem cells or neural progenitor cells.

4. The method of claim 1 , wherein the stem cells overexpressing the vascular endothelial growth factor (VEGF) reduce a cerebral inflammation and inhibit cholesterol or sphingolipid accumulation.

5. The method of claim 1 , wherein the composition is a pharmaceutical composition.

Assignees

• Kyungpook Nat Univ Ind Academic Coop Found

Inventors

• Bae Jae Sung
• Jin Hee Kyung
• Park Min Hee

Classifications

• A61P25/28 Primary

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K9/00

  Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title

• A61K35/545

  Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title

• A61K35/12 Primary

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title